Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
-Reuters
UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $420 to $385.
The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 1.0 to 2.5 percent and an estimated ...
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $2....
- SEC Filing
480 out of 500 S&P 500 companies are trading below analysts' price targets, indicating potential profit opportunities. ...
The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more bro...
Last will remain part of Bio-Rad's executive leadership team to ensure a smooth transition while the company conducts a sea...
